<DOC>
	<DOCNO>NCT01051388</DOCNO>
	<brief_summary>The aim study evaluate efficacy proton pump inhibitor ( PPI ) , compare mucosal defensive drug , prevention recurrence gastric and/or duodenal ulcer 12 week observation patient receive low-dose aspirin vascular protection .</brief_summary>
	<brief_title>Cardio-cerebrovascular Disease Aspirin Ulcer Relapse Evaluation</brief_title>
	<detailed_description>The event recurrence gastric and/or duodenal ulcer evaluate due blind manner specialized endoscopists pre- post administration 12 week administration PPI ( Rabeprazole sodium 10 mg 20 mg tablet day ) mucosal defensive drug ( Gefarnate 50mg Capsule twice day ) .</detailed_description>
	<mesh_term>Cerebrovascular Disorders</mesh_term>
	<mesh_term>Aspirin</mesh_term>
	<mesh_term>Rabeprazole</mesh_term>
	<mesh_term>Gefarnate</mesh_term>
	<criteria>patient ischemic heart failure vascular disease brain patient take lowdose aspirin prevent relapse vascular diseases patient experience gastric and/or duodenal ulcer study endoscopy patient without active gastric duodenal ulcer 20 year old outpatient patient write informed consent patient ischemic heart failure , acute phase , unstable condition 6 month stentinstillation patient brain vascular disease , acute phase , unstable condition 3 month first attack patient uncontrolled complicate disease , example thrombocytopenia , unsuitable study judge investigator patient treat steroid hormone patient woman , pregnant lactate childbearing patient alcoholism patient show hypersensitivity test drug patient enrol another clinical study patient judge unsuitable investigator</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2011</verification_date>
	<keyword>The efficacy PPI</keyword>
	<keyword>Patients receive low-dose aspirin vascular protection</keyword>
</DOC>